Conditional Survival in Patients with Del(5q) Myelodysplastic Syndromes Treated with Lenalidomide

被引：0

作者：

Gerds, Aaron T. ^{[1
]}

List, Alan F. ^{[2
]}

Giagounidis, Aristoteles ^{[3
]}

Hellstrom-Lindberg, Eva ^{[4
]}

Li, Jack Shiansong ^{[5
]}

Swern, Arlene S. ^{[5
]}

Sugrue, Mary M. ^{[5
]}

Fenaux, Pierre ^{[6
]}

Sekeres, Mikkael A. ^{[7
]}

机构：

[1] Cleveland Clin, Leukemia Program, Cleveland, OH 44106 USA

[2] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Div Clin Sci, Tampa, FL 33612 USA

[3] Marien Hosp, Dusseldorf, Germany

[4] Karolinska Univ Hosp, Stockholm, Sweden

[5] Celgene Corp, Summit, NJ USA

[6] Univ Paris 07, Hop St Louis, Serv Hematol Seniors, Paris, France

[7] Cleveland Clin, Dept Hematol & Med Oncol, Cleveland, OH 44106 USA

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[1] Lenalidomide for del(5q) and Non-del(5q) Myelodysplastic Syndromes
Giagounidis, Aristoteles A. N.
SEMINARS IN HEMATOLOGY, 2012, 49 (04) : 312 - 322
[2] Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond
Talati, Chetasi
Sallman, David
List, Alan
SEMINARS IN HEMATOLOGY, 2017, 54 (03) : 159 - 166
[3] DEFINING LIKELIHOOD OF FUTURE RESPONSE IN PATIENTS WITH DEL(5Q) MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH LENALIDOMIDE
Gerds, A. T.
List, A. F.
Giagounidis, A.
Hellstrom-Lindberg, E.
Li, J. Shiansong
Swern, A. S.
Sugrue, M. M.
Fenaux, P.
Sekeres, M. A.
LEUKEMIA RESEARCH, 2015, 39 : S109 - S109
[4] MOLECULAR MECHANISMS OF LENALIDOMIDE RESISTANCE IN DEL(5Q) MYELODYSPLASTIC SYNDROMES
Martinez-Hoyer, Sergio
Deng, Yu
Parker, Jeremy
Jiang, Jihong
Docking, Roderick
Mo, Angela
Gharaee, Nadia
Jadersten, Martin
Kulasekararaj, Austin
Malcovati, Luca
List, Alan
Hellstrom-Lindberg, Eva
Platzbecker, Uwe
Karsan, Aly
EXPERIMENTAL HEMATOLOGY, 2020, 88 : S72 - S72
[5] MYELODYSPLASTIC SYNDROME WITH DEL(5Q) AND LENALIDOMIDE
Gritsaev, S. V.
Martinkevitch, I. S.
Petrova, E. V.
GEMATOLOGIYA I TRANSFUZIOLOGIYA, 2013, 58 (02): : 3 - 10
[6] Survival of patients with de novo myelodysplastic syndromes (MDS) and del(5q)
Gritsaev, S.
Martinkevitch, I.
Petrova, E.
Kostroma, I.
Ivanova, M.
Sergeev, A.
Tiranova, S.
Potichonova, N.
LEUKEMIA RESEARCH, 2013, 37 : S88 - S88
[7] Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes
Heise, Carla
Carter, Troy
Schafer, Peter
Chopra, Rajesh
EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (10) : 1663 - 1672
[8] Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations
Mallo, Mar
del Rey, Monica
Ibanez, Mariam
Jose Calasanz, Ma
Arenillas, Leonor
Jose Larrayoz, Ma
Pedro, Carmen
Jerez, Andres
Maciejewski, Jaroslaw
Costa, Dolors
Nomdedeu, Meritxell
Diez-Campelo, Maria
Lumbreras, Eva
Gonzalez-Martinez, Teresa
Marugan, Isabel
Such, Esperanza
Cervera, Jose
Cigudosa, Juan C.
Alvarez, Sara
Florensa, Lourdes
Hernandez, Jesus Ma
Sole, Francesc
BRITISH JOURNAL OF HAEMATOLOGY, 2013, 162 (01) : 74 - 86
[9] Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?
Vozella, Federico
Latagliata, Roberto
Carmosino, Ida
Volpicelli, Paola
Montagna, Chiara
Romano, Angela
Roberto, Amanda
Finsinger, Paola
Mancini, Marco
Breccia, Massimo
Oliva, Esther
Alimena, Giuliana
HEMATOLOGICAL ONCOLOGY, 2015, 33 (01) : 48 - 51
[10] Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study
Matsuda, Akira
Taniwaki, Masafumi
Jinnai, Itsuro
Harada, Hironori
Watanabe, Mitsumasa
Suzuki, Kenshi
Yanagita, Soshi
Suzuki, Takahiro
Yoshida, Yataro
Kimura, Akiro
Tsudo, Mitsuru
Tohyama, Kaoru
Takatoku, Masaaki
Ozawa, Keiya
LEUKEMIA RESEARCH, 2012, 36 (05) : 575 - 580

← 1 2 3 4 5 →